Navigation Links
Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
Date:7/30/2008

LONDON, July 30 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading European RNAi focused biotechnology company, today announces that its partner, Quark Pharmaceuticals Inc. ("Quark") together with Pfizer, has commenced a Phase II clinical trial with RTP-801i-14 (PF-4523655), a small interfering RNA (siRNA) therapeutic product based on Silence's AtuRNAi technology. Its initiation triggers a $1.9 million milestone payment to Silence from Quark.

The study is designed to evaluate the effectiveness of the candidate in improving visual acuity compared to laser treatment in patients with diabetic macular oedema. The Phase II study is being funded and is conducted by Pfizer Inc. in collaboration with Quark. Pfizer in-licensed RTP-801i-14 from Quark in a deal announced in 2006 for the treatment of age-related macular degeneration (AMD) and other ophthalmologic and non-ophthalmologic indications.

Diabetic macular oedema results in the macula swelling and surrounding blood vessels dilating to compensate for this. The dilated vessels are generally leaky, resulting in fluid build-up in the macula, which in turn causes the macula to swell and cease to function. Diabetic macular oedema is the most common cause of visual impairment in patients with non-proliferative retinopathy. Approximately 14% of people with diabetes have diabetic macular oedema with prevalence increasing to 29% for people with diabetes who use insulin for more than 20 years.

In December 2004 Quark and Silence Therapeutics AG signed a Collaboration Agreement on the development of siRNA molecules for the gene target RTP-801, which resulted in RTP801i-14, a 19 base pairs long blunt-ended AtuRNAi (siRNA) molecule and also provided Quark with a license to AtuRNAi technology. In addition a second agreement (Option and License Agreement) was signed in April 2005, and expanded in 2007, to provide Quark with options for non-exclusive licenses to develop additional molecules agains
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
2. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
3. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
4. Silence Therapeutics Announces Board Changes
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
8. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
9. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)... BOTHELL, Wash. , Oct. 30, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s third quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... TUSTIN, Calif., Jan. 6, 2012 Radient Pharmaceuticals Corporation ... Vitro Diagnostic (IVD) cancer tests, today announced that ... will be launched with a print ad that ... throughout 2012.  These journals have high circulation among ...
... WAYNE, N.J., Jan. 6, 2012  Cascade Medical ... proprietary platelet-rich plasma (PRP) and platelet-rich fibrin matrix (PRFM) ... tissue and bone repair, announced the sale of their ... ConMed Linvatec for the worldwide orthopedic, dental, and wound ...
Cached Medicine Technology:Radient Pharmaceuticals Announces New Advertisement for Oncology Publications 2Cascade Medical Enterprises, LLC Announces the Sale of Their Orthopedic Business 2
(Date:10/30/2014)... 2014 Graphics, coding, typography and search ... the craft of web design and require thorough knowledge ... simpler solution to create a website can be as ... information, customer reviews and Facebook posts all accumulate on ... the next evolution of how a business can develop ...
(Date:10/30/2014)... 2014 High efficacy and low ... the medical-grade skin care domain: Cosmederm, the specialty ... potent topical dermatological products, today announces the launch ... with patented COSMEDERM®-7 anti-irritant technology. , Formulated ... and 70%) and a low pH (pH 1.2 ...
(Date:10/30/2014)... October 30, 2014 PreDiabetes Centers ... PreD Store shoppers with a supply of sugardown®, ... to reduce post-meal blood sugar spikes. Learning how to ... an important part of a diabetes prevention plan. , ... receive one complimentary tube of sugardown. The offer expires ...
(Date:10/30/2014)... Radio listeners who indicate use of four ... of traditional radio commercials and have overwhelmingly endorsed custom ... a purchasing decision. , Those are some highlights from ... radio marketing company CRN International. The research is now ... respondents who indicated they have purchased or considered purchase ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, ... genes have been identified that appear linked to autism ... say they are on their way to discovering up ... disorder. Autism spectrum disorders include a range of ... repetitive behaviors. An estimated one in 68 U.S. children ...
Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... by researchers at the University of Southern California suggests that ... found that a storyline on the primetime NBC network drama ... habits had a positive impact on the attitudes and behaviors ... the Sept. 14 Journal of Health Communication and now available ...
... warning, experts say , SATURDAY, Sept. 22 (HealthDay News) ... be so silent, experts say. , That,s why women ... to possible symptoms of ovarian cancer, according to a ... who are trying to increase awareness about the disease. ...
... Sept. 21 We may have worked hard to ... barbecues, beach lounging and,ball games may have taken a ... back into shape and back into the one thing ... report from Kellogg,s at:, http://media.medialink.com/WebNR.aspx?story=33869 Registered journalists ...
... The following is a,statement by Robert Greenstein, ... Priorities, on the new congressional SCHIP agreement:, ... million,low-income uninsured children, a major accomplishment. Contrary to ... would gain coverage are poor,and near-poor children who ...
... it is to persist, experts say, , , FRIDAY, Sept. 21 (HealthDay ... rite of passage. But new research suggests it has a darker ... people who start to drink at a younger age more likely ... be injured, to be in motor vehicle crashes and to be ...
... that a chemical chain reaction that controls organ size ... the difference between normal growth and cancer. The study, ... how organs can grow uncontrollably huge and become cancerous ... chain reaction, a domino-like chain of events we call ...
Cached Medicine News:Health News:ER episode impacts viewers' health knowledge and behavior 2Health News:Pelvic Exams Can Help Spot Ovarian Cancer 2Health News:Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement 2Health News:Teenage Drinking Can Spell Lasting Trouble 2Health News:Teenage Drinking Can Spell Lasting Trouble 3Health News:Controlling for size may also prevent cancer 2
Stainless steel plain Steinman Pins available in point types A through F....
Full pin skeletal traction pins with cove point....
Calibrated Guide Pins have a 12.7 mm calibration and are available in plain, with a threaded tip, or with a trocar point....
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
Medicine Products: